CareDx (CDNA) director sells 28,779 shares and exercises options
Rhea-AI Filing Summary
CareDx, Inc. director Hannah Valantine reported multiple equity transactions in Common Stock on July 16, 2026. She sold a total of 28,779 shares, including 28,679 shares at a weighted average price of $36.1445 (individual trades from $35.55 to $36.50) and 100 shares at $36.55, under a Rule 10b5-1 trading plan adopted on December 11, 2025. She also exercised fully vested stock options for 28,779 shares at exercise prices of $7.96, $14.19 and $20.56 per share. Following the reported transactions, she held 36,786 shares of CareDx Common Stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 28,779 shares ($1,040,243)
Net Sell
8 txns
Insider
Valantine Hannah
Role
Director
Sold
28,779 shs ($1.04M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,606 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 16,048 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 5,125 | $0.00 | -- |
| Exercise | Common Stock | 7,606 | $20.56 | $156K |
| Exercise | Common Stock | 16,048 | $14.19 | $228K |
| Exercise | Common Stock | 5,125 | $7.96 | $41K |
| Sale | Common Stock | 28,679 | $36.1445 | $1.04M |
| Sale | Common Stock | 100 | $36.55 | $4K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 44,292 shares (Direct)
Footnotes (1)
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option is fully vested.
Key Figures
Shares sold: 28,779 shares
Weighted avg sale price: $36.1445 per share
Additional sale price: $36.55 per share
+3 more
6 metrics
Shares sold
28,779 shares
Aggregate CareDx Common Stock sold on 2026-07-16
Weighted avg sale price
$36.1445 per share
For 28,679 shares sold in multiple trades between $35.55 and $36.50
Additional sale price
$36.55 per share
Price for 100 CareDx Common shares sold on 2026-07-16
Options exercised
28,779 shares
Common shares acquired via option exercises at $7.96, $14.19 and $20.56
Post-transaction holdings
36,786 shares
Direct CareDx Common Stock ownership after reported transactions on 2026-07-16
Rule 10b5-1 plan adoption
December 11, 2025
Adoption date of trading plan governing the reported stock sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did CareDx (CDNA) director Hannah Valantine report?
Hannah Valantine reported selling 28,779 CareDx shares and exercising stock options for 28,779 shares of Common Stock on July 16, 2026. The sales were open-market transactions and the option exercises converted derivative awards into common shares.
What stock options did Hannah Valantine exercise in CareDx (CDNA)?
She exercised fully vested stock options covering 28,779 shares of CareDx Common Stock. The options had exercise prices of $7.96, $14.19 and $20.56 per share, and the corresponding option positions were reduced as they were converted into common shares.